PA
ENSC icon

Perceptive Advisors’s Ensysce Biosciences ENSC Stock Holding History

Perceptive Advisors’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.1K Hold
86,666
– – ﹤0.01% 108
2026
Q1 		$46.7K Hold
86,666
– – ﹤0.01% 93
2025
Q4 		$79.7K Hold
86,666
– – ﹤0.01% 115
2025
Q3 		$205K Hold
86,666
– – 0.01% 90
2025
Q2 		$193K Hold
86,666
– – 0.01% 83
2025
Q1 		$222K Hold
86,666
– – 0.01% 84
2024
Q4 		$705K Buy
+86,666
New +$597K 0.02% 94

Other funds holding ENSC

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TIAM2
Tru Independence Asset Management 2 Portland, Oregon $185M AUM 20.3% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Perceptive Advisors's ENSC Position: Q2 2026 in Review

Perceptive Advisors held its Ensysce Biosciences (ENSC) position steady in Q2 2026 at 86,666 shares worth $25.1K. The position accounts for ﹤0.01% of the portfolio, ranked #108.

Perceptive Advisors first reported a position in ENSC in Q4 2024 and has held it in 7 quarters since. The position peaked at $705K in Q4 2024. 18 funds tracked by Wall St. Rank hold ENSC as of Q2 2026.

  • Perceptive Advisors held 86,666 shares of Ensysce Biosciences worth $25.1K as of Q2 2026.
  • Perceptive Advisors left its Ensysce Biosciences share count unchanged in Q2 2026.
  • Ensysce Biosciences made up ﹤0.01% of Perceptive Advisors's portfolio in Q2 2026, its #108 holding.
  • Perceptive Advisors first reported a position in Ensysce Biosciences in Q4 2024 and has held it in 7 quarters since.
  • Perceptive Advisors's Ensysce Biosciences position peaked at $705K in Q4 2024.
  • 18 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.